Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | recruiting | Phase 4 | 295 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 4 | 75 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07094048 | Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager(CHUQUL_HO001) | recruiting | Phase 4 | 80 | CHU de Quebec-Universite LavalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06057402 | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)(MagnetisMM15) | recruiting | Phase 4 | 80 | PfizerINDUSTRY | 7 | Jul 1, 2026 | clinicaltrials |
| NCT07191379 | Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma(SCILLA) | not yet recruiting | Phase 4 | 50 | Odense University HospitalOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT03934684 | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | completed | Phase 4 | 101 | AmgenINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | terminated | Phase 4 | 141 | TakedaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07474961 | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.(BLOOD-dose) | not yet recruiting | Phase 4 | 400 | Anne Louise Tølbøll SørensenOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07334535 | Isa-VRD in TIE HRMM | not yet recruiting | Phase 4 | 117 | Peking Union Medical College HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05722405 | Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma | recruiting | Phase 4 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04952766 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults(EREVA) | completed | Phase 4 | 196 | Centre Hospitalier Régional d'OrléansOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03829371 | STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | active not recruiting | Phase 4 | 450 | University of Turin, ItalyOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05511428 | Home Based Daratumumab Administration for Patients With Multiple Myeloma | completed | Phase 4 | 20 | Thomas Jefferson UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07025005 | Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)(VRd MM Fibrate) | recruiting | Phase 4 | 44 | Tanta UniversityOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | active not recruiting | Phase 4 | 101 | National Taiwan University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06409702 | Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | recruiting | Phase 4 | 59 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05944783 | Bioequivalence Studies of Dasatinib 100 Mg(BE-Dasatinib) | not yet recruiting | Phase 4 | 46 | Centro de Atencion e Investigacion MedicaNETWORK | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04217967 | Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | completed | Phase 4 | 211 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06425276 | Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | completed | Phase 4 | 67 | CASI Pharmaceuticals (China) Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT00733538 | Stage I Multiple Myeloma Treatment(IFM-01-04) | completed | Phase 4 | 89 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05855122 | Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients | unknown | Phase 4 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT04348006 | Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients(MM) | withdrawn | Phase 4 | 0 | Al-Rasheed University CollegeOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02286830 | Prolonged Protection From Bone Disease in Multiple Myeloma(Magnolia) | completed | Phase 4 | 158 | Thomas LundOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03619252 | Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents | completed | Phase 4 | 36 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT04989140 | Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide | unknown | Phase 4 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00622505 | Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants(Z-MARK) | completed | Phase 4 | 121 | Novartis PharmaceuticalsINDUSTRY | 1 | May 26, 2021 | clinicaltrials |
| NCT01087008 | Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse(AZABACHE) | completed | Phase 4 | 103 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01731886 | Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | completed | Phase 4 | 60 | Columbia UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02577783 | PDD vs PAD to Treat Initially Diagnosed MM | unknown | Phase 4 | 64 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02773550 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma(Velcadito) | terminated | Phase 4 | 24 | Basque Health ServiceOTHER_GOV | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02958969 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma | completed | Phase 4 | 50 | Gregory PiazzaOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03908138 | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | unknown | Phase 4 | 120 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02559154 | Modified Bortezomib-based Combination Therapy for Multiple Myeloma | unknown | Phase 4 | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00211211 | FREE Study - Fracture Reduction Evaluation | completed | Phase 4 | 300 | Medtronic Spine LLCINDUSTRY | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01410929 | Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma(MM) | withdrawn | Phase 4 | 0 | DFINE Inc.INDUSTRY | 0 | Jan 20, 2017 | clinicaltrials |
| NCT02268890 | A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | completed | Phase 4 | 18 | Johnson & Johnson Taiwan LtdINDUSTRY | 1 | Jul 11, 2016 | clinicaltrials |
| NCT00242528 | Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. | withdrawn | Phase 4 | 0 | NovartisINDUSTRY | 0 | Apr 14, 2015 | clinicaltrials |
| NCT00352703 | PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation | completed | Phase 4 | 145 | Swedish Orphan BiovitrumINDUSTRY | 0 | Nov 3, 2014 | clinicaltrials |
| NCT01868828 | A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma | unknown | Phase 4 | 50 | Peking University People's HospitalOTHER | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00652041 | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma(TaCyDexVMP7) | completed | Phase 4 | 40 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials